复方苦参注射液联合放射治疗食管癌的临床研究

目的：探讨复方苦参注射液联合后程加速超分割放射疗法（late course accelerated hyperfractional radiotherapy，LCAHR）治疗食管癌的减毒增效作用及毒副反应。方珐：将68例食管鳞癌患者随机分为复方苦参注射液联合LCAHR治疗（A组，33例）和仅用LCAHR治疗（B组，35例）。治疗期为1999年10月～2002年12月。监测各项实验室指标，并对近期疗效、生存质量和毒副反应进行评定。结果：经随访4～67个月，有效率A组93．3％，B组80．0％，两组比较无显著性差异（P〉0．05）。1、2、3年的局控率和生存率：A组分别为81．8％、69．7％、57．5％和75．8％、63．6％、51．5％；B组分别为74．3％、54．3％、48．6％和68．6％、54．3％、45．7％，两组间差异无显著性意义（P〉0．05）。所有患者的生活质量、卡氏评分、体重、白细胞数、放射性食管炎等都明显改善，且A组优于B组（P〈0．05，P〈0．01）。结论：复方苦参注射液联合LCAHR治疗食管癌患者毒副反应轻，近期疗效较好。

Clinical observation of the compound Kushen injection and radiotherapy in treatment of patients with esophageal carcinoma

Objective: To study the synergic therapeutic efficacy and toxic reaction of compound Kushen(radix sophorae flavescentis) injection combined with late course accelerated hyperfractional radiotherapy(LCAHR) in treatment of patients with esophageal carcinomas.(Methods:) Sixty-eight patients with esophageal squmous cell carcinoma were treated from October 1999 to December 2002.They were randomly divided into two groups: 33 cases treated with compound Kushen injection combined with LCAHR in group A and 35 cases treated with only LCAHR in group B.All cases were followed up for 4-67 months.The results of laboratory(examination,) short-term response and toxicity,quality of life were analyzed.Results: The responsive rates in group A and group B were 93.3% and 80.0%,respectively,with no significant difference between the two groups(P>0.05).The 1,2 and 3-year local control rates and survival rates in group A were 81.8%,69.7%,57.5% and 75.8%,63.6%,51.5%,respectively.Those in group B were 74.3%,54.3%,48.6% and 68.6%,54.3%,45.7%,respectively.There was no significant difference between the two groups(P>0.05).Moreover,the living quality of patients,Karnofsky scores,body weight,white blood cell count and acute radiation-induced esophagitis were obviously improved in all patients and were better in group A than in group B(P<0.05,P<0.01).Conclusion:Compound Kushen injection combined with LCAHR can be safely used in patients with(esophageal) carcinomas and its short-term response is quite satisfactory.It may be worthy of further clinical investigation.